Poseida Therapeutics Inc. (PSTX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Poseida Therapeutics Inc. (PSTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

9.50

0.00 (0.00%)

At close: Jan 07, 2025, 9:00 PM

undefined% (undefined)

Bid	9.53
Market Cap	925.92M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.63
PE Ratio (ttm)	-15.08
Forward PE	n/a
Analyst	Hold

Ask	9.55
Volume	21,344,052
Avg. Volume (20D)	1,707,331
Open	9.58
Previous Close	9.50
Day's Range	9.50 - 9.58
52-Week Range	1.87 - 9.67
Beta	undefined

About PSTX

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patient...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 10, 2020

Employees 350

Stock Exchange NASDAQ

Ticker Symbol PSTX

Website https://www.poseida.com

Analyst Forecast

According to 3 analyst ratings, the average rating for PSTX stock is "Hold." The 12-month stock price forecast is $9, which is a decrease of -5.26% from the latest price.

Buy 0.00%

Hold 100.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Poseida Therapeutics Inc. is scheduled to release its earnings on Mar 6, 2025, during market hours.
Analysts project revenue of $21.25M, reflecting a -14.98% YoY shrinking and earnings per share of -0.36, making a 33.33% increase YoY.

Why Price Moved

1 month ago · Source

+227.97%

Poseida Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

2 months ago · Source

+5.12%

Poseida Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results.

News

1 week ago · proactiveinvestors.com

Roche set to finalise $1.5bn Poseida Therapeutics takeover

Swiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Poseida Therapeutics will be completed on Wednesday. Roche on Wednesday said it had been accepted for p...

1 week ago · reuters.com

Roche to complete acquisition of U.S. biopharma company Poseida

Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp.

3 weeks ago · businesswire.com

PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Poseida Therapeutics, Inc. (NASDAQ: PSTX) to Roche Holdings, Inc. for $9.00 per share in ...

1 month ago · zacks.com

Poseida Therapeutics, Inc. (PSTX) Hits Fresh High: Is There Still Room to Run?

Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

1 month ago · zacks.com

Should You Buy Poseida Therapeutics, Inc. (PSTX) After Golden Cross?

From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pick, as it just reached a key level of support. PSTX's 50-day simple moving average crossed above its 20...

1 month ago · businesswire.com

POSEIDA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Poseida Therapeutics, Inc. - PSTX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Poseida Therapeu...

1 month ago · zacks.com

Wall Street Analysts Think Poseida Therapeutics (PSTX) Could Surge 49.25%: Read This Before Placing a Bet

The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni...

1 month ago · zacks.com

Poseida Therapeutics, Inc. (PSTX) Hit a 52 Week High, Can the Run Continue?

Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

1 month ago · invezz.com

Poseida shares triple on Tuesday, boosted by Roche collaboration

Shares of Poseida Therapeutics Inc (NASDAQ: PSTX) more than tripled this morning after Roche Holding (SWX: ROG) said it will buy the clinical-stage biopharmaceutical company for about $1.5 billion. Ro...

1 month ago · barrons.com

Why This Gene-Therapy Company's Stock Is Rising 228%

Poseida Therapeutics, a cell therapy company, is being acquired by Roche in a $1.5 billion deal.

1 month ago · businesswire.com

Shareholder Alert: Ademi LLP investigates whether Poseida Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Poseida (Nasdaq: PSTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Roche. Click here to learn how...

1 month ago · benzinga.com

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

On Tuesday, Roche Holdings AG RHHBY agreed to acquire Poseida Therapeutics, Inc. PSTX for an equity value of approximately $1.5 billion on a fully diluted basis.

1 month ago · reuters.com

Roche to acquire US-based Poseida Therapeutics

Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday.

2 months ago · zacks.com

Poseida Therapeutics, Inc. (PSTX) Is Up 24.70% in One Week: What You Should Know

Does Poseida Therapeutics, Inc. (PSTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 months ago · zacks.com

Poseida Therapeutics, Inc. (PSTX) Q3 Earnings and Revenues Beat Estimates

Poseida Therapeutics, Inc. (PSTX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to loss of $0.35 per share a yea...